Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer

NCT01234051 | Unknown Phase 2

• 1 other identifier: KSWOG 2010-1
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.Goals
2. 2.The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy Secondary goals are to:evaluate the treatment-related toxicities of this combination, investigate progression-free survival (PFS) and overall survival (OS) in this population
3. 3.Design

Conditions

Biliary Tract Cancer

Outcome Measures

Primary Outcomes (1)

• Response rate

  2years

Secondary Outcomes (3)

• Treatment-related toxicities

  2 years

• Progression free survival

  2 years

• Overall survival

  2 years

Study Arms (1)

Docetaxel, oxaliplatin, palliative chemotherapy

EXPERIMENTAL

Drug: Docetaxel, Oxaliplatin

Interventions

Docetaxel, Oxaliplatin DRUG

1\. Treatment Schedule 1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required. 1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days.

Docetaxel, oxaliplatin, palliative chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically
• Unresectable locally advanced, metastatic, or recurrent biliary tract cancer
• Patients must be ≥ 18 years old of age
• ECOG performance status ≤ 2 (see Appendix C)
• At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (see Appendix D)
• Estimated life expectancy of more than 3 months
• Adequate bone marrow function (absolute neutrophil count \[ANC\] ≥ 1,500/µL, hemoglobin ≥ 9.0 g/dL \[correction by transfusion is acceptable\], and platelets ≥ 100,000/µL)
• Adequate kidney function (serum creatinine \< 1.5 x upper limit of normal \[ULN\])
• Adequate liver function (serum total bilirubin \< 3xULN; serum transaminases levels \< 5xUNL)
• Provision of fully informed consent prior to any study specific procedures

You may not qualify if:

• Other tumor type than adenocarcinoma
• Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy)
• Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥5 years)
• Patients who received radiotherapy on target lesion within 6 months prior to study treatment
• Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases
• Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery
• Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception
• Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment \[NYHA class III or IV\], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
• Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy

Sponsors & Collaborators

• Korean South West Oncology Group: lead

Study Sites (1)

Eun Ki Song

Chonbuk, South Korea

RECRUITING

MeSH Terms

Conditions

Biliary Tract Neoplasms

Interventions

Docetaxel; Oxaliplatin

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Biliary Tract Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Coordination Complexes

Study Officials

• Eun Ki Song

  Chonbuk National Universitiy Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Eun Ki Song

CONTACT

+82-63-250-1245; eksong@jbnu.ac.kr

Hwan Jung Yun

CONTACT

+82-42-280-7157; hjyun@cnu.ac.kr

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2010
• First Posted: November 4, 2010
• Study Start: November 1, 2010
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: December 12, 2011

Record last verified: 2010-11

Locations

KR (1)